New Strong Sell Stocks for June 23rd
ARR, AMTB and AMPH have been added to the Zacks Rank #5 (Strong Sell) List on June 23rd, 2026.
AMPH - Amphastar Pharmaceuticals, Inc.
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$20.50
DETAILS
HIGH:
$22.00
LOW:
$19.00
MEDIAN:
$20.50
CONSENSUS:
$20.50
UPSIDE:
3.82%
Stock News
Amphastar Pharmaceuticals Pivots to Proprietary Drugs, Biosimilars for Growth
Amphastar Pharmaceuticals NASDAQ: AMPH is positioning itself for a broader shift from complex generics toward proprietary medicines and biosimilars, Chief Financial Officer and Executive Vice President of Finance Bill Peters told investors at the East Coast IDEAS Conference.
Amphastar Pharmaceuticals, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, June 08, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) or certain of its executive officers violated federal securities laws. The investigation focuses on investors' losses and whether they may be recovered under federal securities laws.
Amphastar Pharmaceuticals Sees Generic Atrovent Fueling 2026 Growth Despite BAQSIMI Drag
Amphastar Pharmaceuticals NASDAQ: AMPH executives told investors at the Jefferies Healthcare Conference that the company is maintaining expectations for mid- to high-single-digit revenue growth in 2026, supported by a new generic launch, Primatene Mist growth and selected API sales from its China business.
Amphastar Pharmaceuticals to Present at the 2026 Jefferies Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESS Newswire / May 27, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration, will be presenting at the 2026 Jefferies Healthcare Conference on Wednesday, June 3, 2026, at 4:55 p.m. ET. For access to the webcast, visit Amphastar Pharmaceuticals' website at http://ir.amphastar.com.
Amphastar Pharmaceuticals Tackles BAQSIMI Discount Pressure, Keeps Sales Outlook
Amphastar Pharmaceuticals NASDAQ: AMPH executives said the company is taking steps to address rebate and discounting pressure on BAQSIMI while maintaining its full-year revenue outlook, according to remarks at the BofA Annual Healthcare Conference.
Amphastar Pharmaceuticals, Inc. (AMPH) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Amphastar Pharmaceuticals, Inc. (AMPH) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Amphastar Pharmaceuticals, Inc. (AMPH) Q1 2026 Earnings Call Transcript
Amphastar Pharmaceuticals, Inc. (AMPH) Q1 2026 Earnings Call Transcript
Compared to Estimates, Amphastar (AMPH) Q1 Earnings: A Look at Key Metrics
Although the revenue and EPS for Amphastar (AMPH) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Amphastar Pharmaceuticals (AMPH) Q1 Earnings Lag Estimates
Amphastar Pharmaceuticals (AMPH) came out with quarterly earnings of $0.42 per share, missing the Zacks Consensus Estimate of $0.7 per share. This compares to earnings of $0.74 per share a year ago.
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026
Net revenues of $171.2 million for the three months ended March 31, 2026 GAAP net income of $6.4 million, or $0.14 per share, for the first quarter Adjusted non-GAAP net income of $19.5 million, or $0.42 per share, for the first quarter Company to hold a conference call today at 2:00 p.m. Pacific Time RANCHO CUCAMONGA, CA / ACCESS Newswire / May 7, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company"), a biopharmaceutical company focused on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products, today reported results for the three months ended March 31, 2026.
Amphastar Pharmaceuticals to Present at the 2026 Bank of America Health Care Conference
RANCHO CUCAMONGA, CA / ACCESS Newswire / May 6, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, will be presenting at the 2026 Bank of America Health Care Conference on Wednesday, May 13, 2026, at 3:00 pm PT. For access to the webcast, visit Amphastar Pharmaceuticals' website at http://ir.amphastar.com.
Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 7, 2026
RANCHO CUCAMONGA, CA / ACCESS Newswire / April 30, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that the Company will release results for its first quarter of 2026, ended March 31, 2026, after the market closes on Thursday, May 7, 2026, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.
AMPH vs. RDY: Which Stock Should Value Investors Buy Now?
Investors interested in stocks from the Medical - Generic Drugs sector have probably already heard of Amphastar Pharmaceuticals (AMPH) and Doctor Reddy's (RDY). But which of these two companies is the best option for those looking for undervalued stocks?
Amphastar Pharmaceuticals (AMPH) Expected to Beat Earnings Estimates: Should You Buy?
Amphastar (AMPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are Investors Undervaluing Amphastar Pharmaceuticals (AMPH) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Amphastar Pharmaceuticals to Present at the 25th Annual Needham Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESS Newswire / April 6, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") announced today that Bill Peters, CFO, Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, and Dan Dischner, SVP of Corp. Communication, will be presenting at the 25th Annual Needham Healthcare Conference on Tuesday, April 14, 2026, at 11:45 am ET. For access to the webcast, visit Amphastar Pharmaceuticals' website at http://ir.amphastar.com.
SG Americas Securities LLC Makes New Investment in Amphastar Pharmaceuticals, Inc. $AMPH
SG Americas Securities LLC purchased a new stake in Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 93,515 shares of the company's stock, valued at approximately $2,504,000. SG Americas Securities LLC owned about 0.20%
Amphastar Pharmaceuticals (NASDAQ:AMPH) Share Price Passes Below Two Hundred Day Moving Average – Should You Sell?
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH - Get Free Report)'s share price crossed below its two hundred day moving average during trading on Tuesday. The stock has a two hundred day moving average of $25.36 and traded as low as $19.27. Amphastar Pharmaceuticals shares last traded at $19.59, with a volume of 534,127 shares. Analysts Set
Amphastar Pharmaceuticals, Inc. (AMPH) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Amphastar Pharmaceuticals, Inc. (AMPH) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Price Targets
Amphastar price target lowered to $20 from $23 at Barclays
$20.00
(was $18.45)
Barclays
Amphastar downgraded to Equal Weight from Overweight at Wells Fargo
$19.00
(was $18.32)
Benjamin Burnett
·
Wells Fargo
Amphastar price target lowered to $21 from $25 at Piper Sandler
$21.00
(was $19.00)
Piper Sandler
Amphastar downgraded to Hold from Buy at Jefferies
$22.00
(was $22.92)
Dennis Ding
·
Jefferies
Amphastar initiated with an Equal Weight at Barclays
$30.00
(was $26.01)
Barclays
Amphastar price target lowered to $32 from $36 at Piper Sandler
$32.00
(was $28.29)
David Amsellem
·
Piper Sandler
Amphastar Pharmaceuticals (AMPH) PT Lowered to $66 at Piper Sandler
$66.00
(was $43.30)
David Amsellem
·
Piper Sandler
Piper Sandler Reiterates Overweight Rating on Amphastar Pharmaceuticals (AMPH)
$71.00
(was $43.31)
David Amsellem
·
Piper Sandler
Amphastar Pharmaceuticals (AMPH) Stock: Why The Price Jumped Up
$35.00
(was $34.30)
David Amsellem
·
Piper Sandler